Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

1914 - Use of Everolimus in Advanced hormone receptor positive metastatic breast cancer in a multicenter national observational study

Date

11 Sep 2017

Session

Poster display session

Presenters

Audrey Lardy-Cleaud

Citation

Annals of Oncology (2017) 28 (suppl_5): v74-v108. 10.1093/annonc/mdx365

Authors

A. Lardy-Cleaud1, P. cottu2, S. Frank2, O. Le Saux3, S. Chabaud1, D. Parent4, B. Pistilli5, M. Debled6, A. Mailliez7, C. Veyret8, T. Petit9, L. Uwer10, S. Guiu11, M. Ung12, E. Chamorey13, P. Arveux14, T. Guesmia15, P. Augereau16, G. Simon15, T. Bachelot17

Author affiliations

  • 1 Biostatistics, Centre Léon Bérard, 69008 - Lyon/FR
  • 2 Medical Oncology, Institut Curie, 75005 - Paris/FR
  • 3 Medical Oncology, Centre Léon Bérard, 69008 - Lyon/FR
  • 4 Medical Oncology, Institut Jean Godinot, 51100 - Reims/FR
  • 5 Medical Oncology, Gustave Roussy, 94800 - Villejuif/FR
  • 6 Medical Oncology, Institute Bergonié, 33076 - Bordeaux/FR
  • 7 Medical Oncology, Centre Oscar Lambret, 59020 - Lille/FR
  • 8 Medical Oncology, Centre Henri Becquerel, 76038 - Rouen/FR
  • 9 Medical Oncology, Centre Paul Strauss Centre de Lutte contre le Cancer, 67065 - Strasbourg/FR
  • 10 Medical Oncology, Institut de Cancérologie de Lorraine - Alexis Vautrin, 54519 - Vandoeuvre les Nancy/FR
  • 11 Medical Oncology, Institut du Cancer de Montpellier, 34090 - Mont pellier/FR
  • 12 Medical Oncology, 'Institut universitaire du cancer de Toulouse, 31059 - toulouse/FR
  • 13 Pharmacy, Centre Antoine Lacassagne, 06189 - Nice/FR
  • 14 Biostatistics, Centre Georges François Leclerc, 21079 - Dijon/FR
  • 15 R&d, Unicancer R&D, 75013 - Paris/FR
  • 16 Medical Oncology, Centre Paul Papin, 49100 - Angers/FR
  • 17 Département D'oncologie Médicale Adulte, Centre Léon Bérard, 69008 - Lyon/FR
More

Resources

Abstract 1914

Background

The everolimus-exemestane combination has been included in the International guidelines for advanced HR+ breast cancer (mBC) since the results of the Bolero-2 trial. Marketing authorization has been granted in France in July 2012. We evaluated the incidence and indication of everolimus (EVE) use before and after marketing authorization and reimbursement.

Methods

All patients who initiated treatment for a newly diagnosed mBC between 01/2008 and 12/2015 in all 18 French Comprehensive Cancer Centers have been included in the real life ESME database, which collects retrospective data using a clinical trial-like methodology.

Results

The ESME program included a total of 16,703 patients of which 9,921 had HR+/HER2- mBC. Median age at metastatic diagnosis was 62.0 year (range 23-96). Visceral metastases were present in 60.3% of cases. Only 4123 patients (41.6%) received endocrine therapy alone as first-line therapy, and 60% were deemed endocrine resistant. Overall, 1,217 (12.3%) pts have received EVE during therapy as of Dec. 2015 (all lines). EVE was given as first line therapy in 117 pts (10% of all EVE pts and 1.2% of pts receiving a first line therapy). In 99/117 pts (85%) EVE was combined with exemestane. Before 2012, EVE was used within clinical trials. After 2012, use of EVE increased steadily. Percentages in the Table refer to the total of pts who received any kind of treatment during a given year of observation (eg 506 pts took EVE in 2015 out of 4435). Median duration of EVE use was 6.0 months (range 0-65) as first line treatment and 3.9 months (range 0-65) in pretreated patients. Patient population and causes of EVE cessation will be detailed at the meeting.Table:

266P

Year20082009201020112012201320142015
N471311133391493506
%0.200.220.300.212.36.68.611.41

Conclusions

In this very large French national and representative cohort of HR+ HER2- mBC, EVE use rose quickly as soon as marketed. EVE was mostly used in pretreated mBC albeit in probably too advanced pts. These data underline the need for physician and patient education for oral therapies.

Clinical trial identification

not applicable

Legal entity responsible for the study

UNICANCER R&D

Funding

UNICANCER

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.